Explore GEN family of websites, social media experiences, blogs and more.

Unleashing ideas.
Strengthening startups.

Back to search results
    Date submitted
  • 02-Dec-2017



Simply extraordinary.

Loco-regional maligneant recurrences of CRC can be reduced by an abundant 40% through the use of our new surgical enterostomy clamp with integrated colon-rectal washout system.

A very simple but revolutionary solution that bridges a critical technological gap in modern mini-invasive surgery.

Our business idea is featured by: negligible Technological Risks, zeroed Scientific Risks but - at the same time: no collateral effects, backward compatibility with existing surgical practices, cheap and operator independent.

We do not claim to have conceived the ultimate solution of the war against the cancer, we simply have the proof of concept of a new device that for sure will help the oncologic surgeon to enhance the life expectancy of his patients at zero extra costs for the community.

Additional Questions

Who is your customer?

Hospitals, clinics.

What problem does this idea/product solve or what market need does it serve?

Adenocarcinomas of the colon-rectum shed viable cells (exfoliated cells), which have the ability to implant into wounded regions of the internal bowel tissue. Through an intraoperative washout of the rectal stump these neoplastic cells - at the origin of malignancy recurrences - are removed mechanically before than lesions to the bowel mucosa happen with the stapling. Intraoperative washout is no longer performed as it became unpractical in modern laparoscopic surgery. Our device allows to make the intraoperative washout possible also in mini-invasive surgery thus combining the oncologic advantages of this technique with the undeniable advantages of the mini-invasive surgery.

What attributes will make this idea/product successful? Why do you believe that those features will create success?

Simply extraordinary. We are firmly convinced that the complexity of an idea is not necessarily synonymous of its validity. Our simple device introduces a ground-breaking scenario in modern oncologic colon-rectal surgery: the well-known and documented intra-operative washout procedure becomes possible also in mini-invasive surgery. The technological risks associated are very low as we already demonstrated its feasibility and manufacturability. Furthermore, our product functionality can rely on more than 60 years of scientific data certifying the oncologic outcomes of the washout; this allows us to claim that also the associated scientific risks are null. Our patented invention, which is simple under the technical point of view, is - at the same - an extremely powerful tool that permits the surgeon to further enhance the current intra-operative washout techniques under many points of view: -The direction of the liquid inoculated (top-down) is optimal with respect to the previous retrograde washout. - There is no need for a third assistant dedicated to perform the washout - The washout can take place exactly on the region interested by the problem - The washout procedure can be standardized.

Explain how you (your team) will execute to make this idea/product successful? What gives you (your team) an advantage over others already in the market or new to this market?

Our team competences spawn across several disciplines. Each member has an enviable track-record of successes in his own field of competences. The big advantage that poses our invention in a privileged position in the biomedical market of the colon-rectal surgery devices is two-fold. First of all, the uniqueness of the device introduces a new, highly impacting oncologic functionality on existing devices. Secondly, the backward compatibility with the existing surgical techniques: our line of new surgical devices adds but does not replace the canonical functionalities of the equivalent instruments, thus allowing our new product to be used also as any other existing surgical device.